Helicobacter pylori resistance in the Russian Federation: a meta-analysis of studies over the past 10 years

被引:5
作者
Andreev, D. N. [1 ]
Maev, I., V [1 ]
Kucheryavyy, Yu A. [1 ]
机构
[1] Yevdokimov Moscow State Univ Med & Dent, Moscow, Russia
关键词
Helicobacter pylori; eradication therapy; resistance; sensitivity; antibacterial drugs; clarithromycin; metronidazole; levofloxacin; tetracycline; ERADICATION THERAPY; DRUG-RESISTANCE; INFECTION; EFFICACY; SCHEME; SAFETY;
D O I
10.26442/00403660.2020.11.000795
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim. Systematization of data on antibiotic resistance of Helicohacter pylori in Russia over the past 10 years. Methods. A search for studies were carried out in electronic dalahases MEDLINE/PubMed, FMBASE, Cochrane, Russian Science Citation Index. We analyzed the papers published over the past 10 years (2011 to 2020). In the final analysis, publications were selected from periodical peer-reviewed foreign and Russian publications, in which validated tests for assessing the microorganism resistance were used with detailed descriptive statistics, which allows the obtained data to be included in the meta-analysis. Results. The final analysis included 11 studies (808 isolates). H. pylori resistance to clarithromycin was 10.39% (95% confidence interval - CI 7.103-14.219), metronidazole - 33.95% (95% CI 15.329-55.639), amoxicillin - 1.35% (95% CI 0.281- 3.202), levofloxacin - 20.0% (95% CI 12.637-28.574), tetracycline - 0.98% (95% CI 0.353-2.163). Double clarithromycin-metronidazole resistance was reported in 2.7% (95% CI 1.136-4.345). Conclusion. This meta-analysis is the first analytical work that allows objectifying the current structure of H. pylori antibiotic resistance in the Russian Federation. The data obtained in the analysis of publications over the past 10 years indicate a low resistance of the microorganism to clarithromycin (less than the regulated threshold of 15%), which allows us to consider the triple regimen of eradication therapy as a firstline therapy in our country.
引用
收藏
页码:24 / 30
页数:7
相关论文
共 42 条
[1]  
Abdulhakov SR, 2012, EXPT CLIN GASTROENTE, V8, P24
[2]  
Aldana LP, 2002, HELICOBACTER, V7, P306
[3]  
Andreev DN, 2018, TERAPEVT ARKH, V90, P27, DOI [https//doi.org/10.26442/terarkh201890827-32, 10.26442/terarkh201890827-32]
[4]   The efficiency and safety of anti-Helicobacter pylori therapy in patients with concomitant chronic hepatitis C [J].
Andreev, D. N. ;
Maev, I. V. ;
Kucheryavyi, Yu. A. ;
Dicheva, D. T. ;
Partsvania-Vinogradova, E. V. .
TERAPEVTICHESKII ARKHIV, 2016, 88 (04) :75-81
[5]  
[Anonymous], 2018, INCIDENCE ENTIRE POP
[6]   European registry Helicobacter pylori (Hp-EuReg) as a tool to evaluate and improve clinical practice in Moscow [J].
Bordin, D. S. ;
Voynovan, I. N. ;
Embutnieks, Yu, V ;
Nyssen, Olga P. ;
Megraud, Francis ;
O'Morain, Colm ;
Gisbert, Javier P. .
TERAPEVTICHESKII ARKHIV, 2020, 92 (02) :12-18
[7]  
Dehnich NN, 2018, CLIN MICROBIOLOGY AN, V20, P42, DOI [10.36488/cmac.2018.1.42-48, DOI 10.36488/CMAC.2018.1.42-48]
[8]  
Dehnich NN, 2016, RUS J GASTROENTEROL, V26, P24
[9]  
Dehnich NN, 2011, RUSSIAN J GASTROENTE, V21, P37, DOI DOI 10.26442/TERARKH201890827-32
[10]   Dynamics of antimicrobial resistance of Helicobacter pylori isolates in the Smolensk region of Russian Federation [J].
Dekhnich, Natalia ;
Ivanchik, Natalie ;
Kozlov, Roman ;
Alimov, Alexander ;
Steshits, Andrey ;
Kirsov, Pavel ;
Pandav, Krunal .
HELICOBACTER, 2018, 23 (06)